Taysha Gene Therapies (TSHA) Invested Capital (2019 - 2026)

Taysha Gene Therapies has disclosed Invested Capital across 8 years of filings, most recently posting $261.9 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $261.9 million, up 375.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $261.9 million (up 375.75% YoY), and the FY2025 annual result was $296.9 million, up 166.25% from the prior year.
• Invested Capital came in at $261.9 million for Q1 2026 at Taysha Gene Therapies, down from $296.9 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $296.9 million in Q4 2025 to a low of -$37.1 million in Q2 2023.
• The 5-year median for Invested Capital is $55.1 million (2025), against an average of $91.4 million.
• Peak annual rise in Invested Capital reached 7796.42% in 2023, while the deepest fall reached 214.17% in 2023.
• Taysha Gene Therapies' Invested Capital stood at $949000.0 in 2022, then soared by 7796.42% to $74.9 million in 2023, then surged by 48.83% to $111.5 million in 2024, then jumped by 166.25% to $296.9 million in 2025, then retreated by 11.78% to $261.9 million in 2026.
• The last three Invested Capital figures came in at $261.9 million (Q1 2026), $296.9 million (Q4 2025), and $219.0 million (Q3 2025), per Business Quant data.